Drug intelligence / Profile preview

inactivated novel coronavirus vaccine (Vero cells)

Development stage
Unknown
Lead developer
Sinovac Biotech
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

The inactivated novel coronavirus vaccine (Vero cells) is a whole-virus, inactivated vaccine developed to prevent COVID-19. The active ingredient is an inactivated SARS-CoV‑2 virus, produced by culturing the virus on Vero cells—kidney epithelial cells from African green monkeys—followed by chemical or heat inactivation to eliminate infectivity while preserving antigenicity. The formulation includes an aluminum hydroxide adjuvant and standard excipients such as disodium hydrogen phosphate and sodium chloride. Upon intramuscular administration, the vaccine induces an immune response that generates neutralizing antibodies against SARS-CoV‑2, providing protection against COVID‑19. It is indicated for active immunization of adults and has demonstrated efficacy across multiple strains of the virus[1][2][3]. Multiple manufacturers produce this type of vaccine under different brand names.

Brand names
CoronaVacCOVILO
Other names
inactivated novel coronavirus vaccine (Vero cells)COVID-19 Vaccine (Vero Cell), InactivatedSARS-CoV-2 Vaccine (Vero Cell), Inactivated

Beyond the preview

Go deeper on inactivated novel coronavirus vaccine (Vero cells).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on inactivated novel coronavirus vaccine (Vero cells).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call